The authors assessed the efficacy and safety of rosuvastatin monotherapy, extended-release (ER) niacin monotherapy, or rosuvastatin and ER niacin combined therapy in patients with atherogenic ...

In the open-label arm, atorvastatin 80mg reduced LDL cholesterol by about 60%, apo B by about 50% (both smaller reductions than with rosuvastatin), and total cholesterol by about 45% (the same).

3. Barter P, Stender S, Morrell J et al. Switching to rosuvastatin from other statins has beneficial effects on Apo B and the Apo B:Apo A-1 ratio. Results from the MERCURY I Trial. 13th ...

Rosuvastatin did not reduce the primary outcome ... NYHA denotes New York Heart Association, LDL low-density lipoprotein, Apo apolipoprotein, HDL high-density lipoprotein, GFR glomerular ...

Rosuvastatin calcium is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, Apo B, non-HDL-C and triglyceride levels, and to increase levels of HDL-C in patients with primary ...

The study results, “Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin ... other important lipid parameters, such as Apo A-I, LDL-C/HDL-C, non-HDL-C/ HDL-C, TC/HDL ...

This Phase 1 open-label study is examining the safety, tolerability and pharmacokinetics of a once-weekly rosuvastatin extended-release capsule (LYN-047) in 16 healthy volunteers in Australia.

Treatment with the anticholesterol medicine rosuvastatin calcium did not reduce the risk of fracture among men and women who had elevated levels of an inflammatory biomarker, according to a report.

Increased levels of the inflammatory biomarker high-sensitivity C-reactive protein predict cardiovascular events. Since statins lower levels of high-sensitivity C-reactive protein as well as ...

NEW DELHI: Glenmark Pharmaceuticals has received final approval from the US health regulator USFDA for rosuvastatin calcium tablets, used in lowering cholesterol. "Glenmark Pharmaceuticals Inc ...